RVMD vs. PCVX, EXEL, IBRX, HALO, CRSP, KRYS, IMVT, RGEN, SWTX, and IOVA
Should you be buying Revolution Medicines stock or one of its competitors? The main competitors of Revolution Medicines include Vaxcyte (PCVX), Exelixis (EXEL), ImmunityBio (IBRX), Halozyme Therapeutics (HALO), CRISPR Therapeutics (CRSP), Krystal Biotech (KRYS), Immunovant (IMVT), Repligen (RGEN), SpringWorks Therapeutics (SWTX), and Iovance Biotherapeutics (IOVA). These companies are all part of the "biological products, except diagnostic" industry.
Revolution Medicines (NASDAQ:RVMD) and Vaxcyte (NASDAQ:PCVX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment.
Revolution Medicines has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500.
Vaxcyte has lower revenue, but higher earnings than Revolution Medicines. Vaxcyte is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines had 8 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Revolution Medicines and 1 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 0.67 beat Revolution Medicines' score of 0.35 indicating that Vaxcyte is being referred to more favorably in the news media.
Revolution Medicines currently has a consensus price target of $41.20, suggesting a potential upside of 5.97%. Vaxcyte has a consensus price target of $78.50, suggesting a potential upside of 16.26%. Given Vaxcyte's higher possible upside, analysts plainly believe Vaxcyte is more favorable than Revolution Medicines.
94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 8.5% of Revolution Medicines shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Vaxcyte's return on equity of -32.04% beat Revolution Medicines' return on equity.
Revolution Medicines received 31 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 68.13% of users gave Revolution Medicines an outperform vote while only 67.39% of users gave Vaxcyte an outperform vote.
Summary
Revolution Medicines beats Vaxcyte on 11 of the 17 factors compared between the two stocks.
Get Revolution Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Revolution Medicines Competitors List
Related Companies and Tools
